NewLink Genetics (NLNK) Receives Daily Media Sentiment Score of 0.17

News coverage about NewLink Genetics (NASDAQ:NLNK) has trended somewhat positive this week, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. NewLink Genetics earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 46.1757470331968 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of NewLink Genetics (NASDAQ NLNK) opened at $8.58 on Friday. NewLink Genetics has a 12-month low of $5.90 and a 12-month high of $25.17. The company has a market capitalization of $320.35, a P/E ratio of -3.52 and a beta of 1.10.

NewLink Genetics (NASDAQ:NLNK) last issued its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.69) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.74) by $0.05. NewLink Genetics had a negative return on equity of 63.39% and a negative net margin of 229.19%. analysts expect that NewLink Genetics will post -2.65 EPS for the current fiscal year.

NLNK has been the subject of several research reports. Bank of America initiated coverage on NewLink Genetics in a research report on Friday, October 13th. They set a “buy” rating and a $22.00 price target for the company. Zacks Investment Research cut NewLink Genetics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. Cantor Fitzgerald reiterated a “buy” rating and set a $26.00 price target on shares of NewLink Genetics in a research report on Thursday, November 2nd. Jefferies Group dropped their price target on NewLink Genetics from $26.00 to $25.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Finally, Stifel Nicolaus boosted their price target on NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Friday, November 3rd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $23.29.

TRADEMARK VIOLATION NOTICE: This story was published by BBNS and is the sole property of of BBNS. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://baseballnewssource.com/markets/newlink-genetics-nlnk-receives-daily-media-sentiment-score-of-0-17/1872700.html.

NewLink Genetics Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Insider Buying and Selling by Quarter for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August
Mookie Betts Awarded Arbitration of $10.5 Million
Mookie Betts Awarded Arbitration of $10.5 Million


Leave a Reply

 
© 2006-2018 BBNS.